The Commonwealth of Independent States - anchored by the Russian Federation and extending across Central Asia, Caucasus and parts of Eastern Europe - is a distinct pharmaceutical market with unique regulatory pathways.
1. EAEU Harmonised Pathway #
The Eurasian Economic Union (EAEU) allows a single lead-country registration with extension to member states:
- Russian Federation
- Belarus
- Kazakhstan
- Kyrgyzstan
- Armenia
Dossier in CTD-aligned format, Russian-language Module 1, GMP inspection typically required.
2. Non-EAEU CIS Markets #
- Uzbekistan (national registration)
- Azerbaijan (national registration)
- Moldova (European-leaning framework)
- Tajikistan, Turkmenistan (national registration)
3. Key Sourcing Considerations #
- Russian-language leaflet and Cyrillic-script carton
- Climatic zone is typically Zone II (Russia) or Zone IVa (Central Asia) - stability data package should cover both
- Payment currency: USD / EUR / RUB considerations for Russian Federation
- Shipping via Black Sea ports (seasonal considerations) or airfreight
- Pharmacovigilance local-reporting obligations
4. GMP Inspection #
Russian Federation registration typically includes an in-person GMP inspection by Russian regulatory authority. Manufacturer site readiness for international inspection is therefore a prerequisite.
5. Patient-Population Priorities #
Central Asian and Caucasus countries have meaningful thalassemia populations driven by historical consanguinity and genetic prevalence. Public-sector procurement through ministries of health supports ongoing access programmes.
6. Taj Pharma in CIS #
DEFRATAJ is supplied to CIS markets through registered distributors, with Russian-language artwork support and EAEU-pathway documentation. See CIS lander.